Despite the individual limitations of sampling for KRAS or GNAS to preoperatively assess IPMN malignancy risk, Bournet et al. sought to evaluate the predictive power of a combinatorial assay examining KRAS, GNAS, and cyst fluid cytopathology [53]. The gene discussed is GNAS; the disease is pancreatic intraductal papillary-mucinous neoplasm.